Evidence map›Paper›PMID 37460875›Full record

ArticleIn vitro cellular & developmental biology. Animal2023

Brevilin A inhibits RANKL-induced osteoclast differentiation and bone resorption.

Jinfu Wei, Zihong Lin, Zeyu Dai, Zibin Zhou, Yonghao Bi, Ruiwu Zheng, Xianghua Hu, Zhaoxin Xu, Guixin Yuan, Weidong Wang

Abstract read
PubMed Publisher
In one paragraph

Article in In vitro cellular & developmental biology. Animal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Jinfu WeiDepartment of Orthopedics, The Second Affiliated Hospital, Shantou University Medical College, Shantou, 515000, Guangdong, China.
Zihong LinDepartment of Shantou Central Hospital, Shantou, 515000, Guangdong, China.
Zeyu DaiDepartment of Orthopedics, The Second Affiliated Hospital, Shantou University Medical College, Shantou, 515000, Guangdong, China.
Zibin ZhouDepartment of Orthopedics, The Second Affiliated Hospital, Shantou University Medical College, Shantou, 515000, Guangdong, China.
Yonghao BiDepartment of Orthopedics, The Second Affiliated Hospital, Shantou University Medical College, Shantou, 515000, Guangdong, China.
Ruiwu ZhengDepartment of Orthopedics, The Second Affiliated Hospital, Shantou University Medical College, Shantou, 515000, Guangdong, China.
Xianghua HuDepartment of Orthopedics, The Second Affiliated Hospital, Shantou University Medical College, Shantou, 515000, Guangdong, China.
Zhaoxin XuDepartment of Orthopedics, The Second Affiliated Hospital, Shantou University Medical College, Shantou, 515000, Guangdong, China.
Guixin YuanDepartment of Orthopedics, The Second Affiliated Hospital, Shantou University Medical College, Shantou, 515000, Guangdong, China. yuixinguan@foxmail.com.
Weidong WangDepartment of Bone and Soft Tissue Oncology Surgery, Cancer Hospital of Shantou University Medical College, Shantou, 515000, Guangdong, China. 07wdwang@stu.edu.cn.ORCID http://orcid.org/0000-0003-3593-9096
Shantou University · CNShantou Central Hospital · CN

Funding

National Natural Science Foundation of China 82103652Shantou Science and Technology Project 190606175268442Shantou Science and Technology Project 220506096490299Traditional Chinese Medicine Bureau of Guangdong Province 20232084
6 · The paper itself

Abstract

Brevilin A (BA) is the primary component of Centipeda minima, which is widely used in Chinese traditional medicine. The anti-inflammatory and anti-tumor properties of BA have been established; however, its function in bone metabolism is not well understood. This study revealed that concentrations of BA below 1.0 µM did not inhibit the proliferation of bone marrow macrophages but did impede the differentiation and bone resorption activity of osteoclasts. Furthermore, BA suppressed the expression of osteoclast-specific genes Mmp9, Acp5, Dc-stamp, Ctsk, and Atp6v0d2. In addition, mTOR, ERK, and NFATc1 activation in bone marrow macrophages were suppressed by BA. As a whole, BA blocks the mTOR and ERK signaling pathways, which is responsible for the development and activity of osteoclasts, and the resorption of bone.

Indexed as

Bone ResorptionOsteoclastsAnimalsCell DifferentiationCrotonatesNFATC Transcription FactorsOsteogenesisRANK LigandSesquiterpenesTOR Serine-Threonine Kinasesbrevilin ACrotonatesNFATC Transcription FactorsRANK LigandSesquiterpenesTOR Serine-Threonine KinasesBrevilin AMAPKmTOROsteoclastogenesis

Identifiers

PMID37460875
OpenAlexW4384561847

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.